Düsseldorf, Germany – June 6th, 2025
LenioBio GmbH, a life sciences company and pioneer in plant-based cell-free protein expression technology, today announced the appointment of Sabine Imamoglu as Chief Operating Officer.
Sabine brings more than 25 years of international experience in the biopharmaceutical industry, including leadership roles at Bayer, Novartis, and Dynavax. She joins LenioBio’s Senior Leadership Team and will oversee all operational functions as the company prepares for its next stage of growth.
Her expertise spans production, including large-scale insulin manufacturing, technical development, and Manufacturing Science and Technology (MSAT). She has supported several product approvals globally and brings deep experience in product lifecycle management and third-party oversight. Sabine is also highly experienced in quality inspections across regulatory bodies.
“LenioBio’s ALiCE® platform opens up exciting possibilities for producing new and complex proteins. I am looking forward to working with a great team on the further development, production, and commercialization of this technology,” said Imamoglu.
André Goerke, CEO of LenioBio, said, “Sabine brings a powerful combination of operational expertise and leadership. Her arrival is perfectly timed as we move closer to broader commercial deployment of ALiCE®.”
About LenioBio
LenioBio GmbH is a life sciences biotech company dedicated to transforming protein production through its proprietary ALiCE® technology. By eliminating the limitations and bottlenecks of traditional cell-based systems, LenioBio empowers researchers to explore new frontiers in protein expression and accelerate the development of cutting-edge therapeutics and diagnostics.
Please visit our website at www.leniobio.com and follow us on LinkedIn.